Understanding Mpox and the Latest Research on Treatment Strategies
In March 2025, new findings presented at the Conference on Retroviruses and Opportunistic Infections (CROI) highlighted the complexities of mpox treatment, particularly concerning the antiviral drug tecovirimat (TPOXX). This in-depth review dives into the implications of these results and the need for innovative future strategies.
Recent Insights from the CROI 2025 Conference
The latest data from an NIH-sponsored trial, released at the 2025 CROI in San Francisco, has presented critical insights into mpox treatment approaches. Specifically, the study focused on the effectiveness of tecovirimat monotherapy against clade II of the mpox virus and the outcomes were striking.
Study Overview: Tecovirimat’s Effectiveness Questioned
Conducted as part of the international STOMP trial (Study of Tecovirimat for Mpox), sponsored by the NIH, the trial was stopped early in late 2024. This decision followed an interim analysis revealing that tecovirimat did not significantly hasten clinical resolution of mpox lesions nor ameliorate pain in adult participants compared to a placebo. The study had enrolled participants from multiple countries including Argentina, Brazil, Japan, Mexico, Peru, Thailand, the United States, and Puerto Rico.
Jeanne Marrazzo, M.D., M.P.H., from the NIH’s National Institute of Allergy and Infectious Diseases, emphasized the importance of such studies for advancing our understanding of mpox—a disease that still poses significant knowledge gaps:
“This study brought us a step forward in better understanding mpox disease and potential treatment strategies. We are grateful to the study team and participants for their contributions to groundbreaking research on a disease that we still do not know enough about.”
Expanding Knowledge on Mpox: Disease and Clade Variations
Mpox, previously known as monkeypox, is primarily transmitted through close contact, including direct engagement with lesions, body fluids, and contaminated materials, as well as through respiratory droplets and sexual contact. There are two main clades of the mpox virus, each varying in terms of geographical distribution and epidemiological significance. Clade I viruses have historically been more prevalent in Central and East African countries, while Clade II caused the notable 2022 global outbreak, with both clades still being subjects of continued public health concern.
The Complexities of Mpox Treatment: Beyond Tecovirimat
The STOMP trial’s findings underscore the challenges in treating mpox, particularly with a lack of significant beneficial outcomes from tecovirimat monotherapy. Key findings from the trial showed no significant differences in lesion resolution or pain improvement between those given the drug and those on a placebo. Interestingly, younger age and the absence of HIV were correlated with faster resolution of the disease, indicating that patient demographics play a role in treatment effectiveness.
Dr. Timothy Wilkin of the University of California, San Diego, articulated the clinical implications:
“Since the start of the clade II outbreak, clinicians treating mpox have had limited evidence to guide their practice. STOMP provided definitive answers on the lack of clinical utility of tecovirimat monotherapy for the randomized population studied. These latest results also highlight that we still have yet to isolate which factors influence mpox disease progression and clinical resolution.”
Future Directions and Research Opportunities
The STOMP trial’s results prompt a critical reevaluation of existing mpox treatment strategies, emphasizing the need for further investigation into alternative therapies. Future research might explore combination therapies, particularly targeting high-risk populations and establishing which factors most significantly impact disease progression.
Approved Treatments and Ongoing Challenges
As of now, there are no mpox-specific treatments approved in the United States. While tecovirimat is FDA-approved for smallpox, its off-label use for mpox lacks the desired efficacy, necessitating a broader spectrum of exploration in therapeutic options.
Global Implications and Further Studies
The PALM007 trial, conducted in the Democratic Republic of the Congo with similar methodologies, concurred with the STOMP findings, illustrating shared global challenges in effectively managing mpox. With no clear treatment pathway yet, mpox management continues to be a critical area for international health organizations, emphasizing the necessity for collaborative, global research efforts.
Conclusion
As we advance in our understanding of mpox, the journey is one of intricate scientific discovery and crucial public health vigilance. The 2025 research findings represent a pivotal point, informing future strategies aimed at mitigating the impact of this formidable virus. To stay informed and updated, reputable sources like the CDC, NIH, and WHO offer continuing insights into evolving mpox dynamics and treatment paradigms.